palladium-carbon

• 分子结构分类: 有机化合物 - 碳氢化合物衍生物
• 英文名称: palladium-carbon
• 英文别名: palladium monocarbide；palladium carbide；Palladiumcarbon；methane;palladium
• 化学式: CPd
• 分子量: 118.431
• InChiKey: UKVIEHSSVKSQBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.63
• 重原子数：
  2
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  8-nitro-5H-pyrimido[5,4-b]indole-2-carboxylic acid ethyl ester 、 palladium-carbon 以 乙酸乙酯 为溶剂， 生成 8-amino-5H-pyrimido[5,4-b]indole-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  Substituted 5H-pyrimido[5,4-b]indoles

  摘要：

  化学式为I的5H-嘧啶并[5,4-b]吲哚，其中R.sup.2为卤素; 氧代二唑基团##STR2##其中R"为具有最多3个碳原子的低级烷基; C.sub.1-5-烷基，环烷基，芳基烷基或芳基; OR.sup.I，SO.sub.nR.sup.I，其中n为0,1或2，或##STR3##其中R.sup.I为氢，C.sub.1-5-烷基，环烷基，芳基烷基或芳基; ##STR4##其中R.sup.II和R.sup.III为氢，C.sub.1-5-烷基，C.sub.3-5-烯基，环烷基，芳基烷基，芳基或与连接的N原子，为5或6成员杂环环; 而R.sup.A为氢; 氧代二唑基团##STR5##其中R"为具有最多3个碳原子的低级烷基; 卤素，硝基，OR.sup.I，SO.sub.nR.sup.I，其中n为0,1或2，##STR6##其中R.sup.I为氢，C.sub.1-5-烷基，环烷基，芳基烷基或芳基; ##STR7##其中R.sup.II和R.sup.III为氢，C.sub.1-5-烷基，环烷基，C.sub.3-5-烯基，芳基烷基，芳基或与连接的N原子，为5或6成员杂环环; 或PO（OR）.sub.2，其中R为C.sub.1-5-烷基，具有与苯二氮平受体结合的强亲和力。这些新化合物适用于精神药物制剂的使用。

  公开号：

  US04564610A1
• 作为产物：
  描述：

  钯 在 CO 作用下， 以 neat (no solvent) 为溶剂， 生成 palladium-carbon
  参考文献：
  名称：

  通过乙烯、乙炔和一氧化碳与钯的相互作用形成间隙钯碳相

  摘要：

  Une phase Pd-C est formee quand Pd est chauffe dans une大气d'乙烯，乙炔或CO。Ce processus fait intervenir le depot d'une surcouche carbonacee，suivie d'une扩散活性物质de C a travers le reseau metallique。练习曲RX

  DOI：

  10.1021/ja00301a031
• 作为试剂：
  描述：

  4-乙炔基苯甲酸甲酯 在 palladium-carbon 、 氢气 作用下， 以 甲苯 为溶剂， 反应 0.25h， 以99.1%的产率得到4-乙烯基苯甲酸甲酯
  参考文献：
  名称：

  PdC_x nanocrystals with tunable compositions for alkyne semihydrogenation

  摘要：

  已报告了一种新颖高效的方法，用于制备可调组成的PdC_x纳米催化剂，以增强炔烃半加氢反应。

  DOI：

  10.1039/c8ta12002a

文献信息

• Carbostyril derivatives
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US04435404A1

  公开（公告）日：1984-03-06

  Novel carbostyril derivative and its salt represented by the general formula (1), ##STR1## wherein R.sup.1 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a phenyl-lower alkyl group; R.sup.2 is a hydrogen atom, a lower alkyl group or a group of the formula ##STR2## wherein A is a lower alkylene group; R.sup.3 is a lower alkyl group, a hydroxy lower alkyl group, a lower alkoxy-lower alkyl group, a lower alkanoyloxy-lower alkyl group or a benzoyloxy-lower alkyl group; and R.sup.4 is a C.sub.3-10 -cycloalkyl group which may have at least one hydroxyl group as the substituent(s) in the cycloalkyl ring, a C.sub.3-10 -cycloalkyl-lower alkyl group, a phenyl group, a phenyl-lower alkyl group which may have at least one lower alkoxy group as the substituent(s) in the phenyl ring, a lower alkyl group which may have at least one hydroxyl group as the substituent(s), a heterocyclic ring residue or a lower alkyl group having one heterocyclic ring residue as the substituent; further, R.sup.3, R.sup.4 and the adjacent nitrogen atom, as well as with or without another nitrogen atom, may form a group of the formula ##STR3## (wherein R.sup.5 is a phenyl group, a C.sub.3-10 -cycloalkyl group or a phenyl-lower alkyl group; and B is a methine group or a nitrogen atom); the carbon-carbon bond between the 3- and 4-positions in the carbostyril skeleton is a single or double bond; the substituted position of the group of the formula ##STR4## is any one of 5-, 6-, 7- or 8-position in the carbostyril skeleton; when the group of the formula ##STR5## is substituted at 5-, 6-, 7- or 8-position in the carbostyril skeleton, then R.sup.2 is a hydrogen atom or a lower alkyl group; alternatively, when R.sup.2 is a group of the formula ##STR6## then 5-, 6-, 7- and 8-positions in the carbostyril skeleton are hydrogen atoms and are not substituted with groups of the formula ##STR7## and when R.sup.3 is a lower alkyl group, then R.sup.4 should be neither of a C.sub.3-10 -cycloalkyl group, a C.sub.3-10 -cycloalkyl-lower alkyl group nor a lower alkyl group, having effects for preventing and treating thrombosis and embolism.

  新型的羧基喹啉衍生物及其盐由通式（1）表示，其中R.sup.1是氢原子，低碳基团，低烯基团或苯基-低碳基团；R.sup.2是氢原子，低碳基团或式##STR2##的基团，其中A是低碳烷基团；R.sup.3是低碳基团，羟基低碳基团，低烷氧基-低碳基团，低烷酰氧基-低碳基团或苯甲酰氧基-低碳基团；R.sup.4是C.sub.3-10-环烷基团，该环烷基团可能至少有一个羟基作为环烷基环上的取代基，C.sub.3-10-环烷基-低碳基团，苯基，苯基-低碳基团，该苯基环上可能至少有一个低烷氧基作为取代基，低碳基，该低碳基可能至少有一个羟基作为取代基，杂环环残基或具有一个杂环环残基作为取代基的低碳基；此外，R.sup.3，R.sup.4和相邻的氮原子，以及有或没有另一个氮原子，可能形成式##STR3##的基团（其中R.sup.5是苯基，C.sub.3-10-环烷基团或苯基-低碳基团；B是亚甲基基团或氮原子）；羧基喹啉骨架中3-和4-位置之间的碳-碳键是单键或双键；式##STR4##的基团的取代位置是羧基喹啉骨架中的5-，6-，7-或8-位置中的任意一个；当式##STR5##的基团在羧基喹啉骨架的5-，6-，7-或8-位置取代时，R.sup.2是氢原子或低碳基团；或者，当R.sup.2是式##STR6##的基团时，羧基喹啉骨架的5-，6-，7-和8-位置是氢原子，并且未被式##STR7##的基团取代；当R.sup.3是低碳基团时，R.sup.4不应是C.sub.3-10-环烷基团，C.sub.3-10-环烷基-低碳基团或低碳基团，具有预防和治疗血栓形成和栓塞的作用。
• Amine compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06329389B1

  公开（公告）日：2001-12-11

  The present invention provides a compound of the formula: wherein Ar represents an aromatic group which may be substituted; X represents methylene, S, SO, SO2 or CO; Y represents a spacer having a main chain of 2 to 5 atoms; n represents an integer of 1 to 5; i) R1 and R2 each represents a hydrogen atom or a lower alkyl which may be substituted, ii) R1 and R2 form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring which may be substituted, or iii) R1 or R2 together with —(CH2)n—N═ form, bonded to a component atom of Ring B, a spiro-ring which may be substituted; Ring A represents an aromatic ring which may be substituted; Ring B represents a 4- to 7-membered nitrogen-containing non-aromatic ring which may be further substituted by alkyl or acyl, with a proviso that X represents S, SO, SO2 or CO when Ring A has as a substituent a group represented by the formula: —NHCOR11 where R11 represents alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or a group represented by the formula: —NHR12 where R12 represents alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, or a salt thereof; which has an excellent somatostatin receptor binding inhibition action.

  本发明提供了一种化合物，其化学式如下： 其中Ar代表可能被取代的芳香基团； X代表亚甲基、S、SO、SO2或CO； Y代表具有2到5个原子的主链的间隔物； n代表1到5的整数； i）R1和R2分别代表氢原子或可能被取代的较低烷基， ii）R1和R2与相邻的氮原子一起形成可能被取代的含氮杂环环，或 iii）R1或R2与—(CH2)n—N═一起形成，与环B的一个组分原子结合，可能被取代的螺环； 环A代表可能被取代的芳香环； 环B代表可能被烷基或酰基进一步取代的4到7成员的含氮非芳香环， 但有一个条件是，当环A具有由下式表示的基团作为取代基时： —NHCOR11 其中R11代表烷基、烷氧基烷基、烷硫基烷基、环烷基、环烷基烷基、芳基、芳基烷基或由下式表示的基团： —NHR12 其中R12代表烷基、环烷基、环烷基烷基、芳基或芳基烷基，或其盐；具有优异的生长抑素受体结合抑制作用。
• Quinoline, naphthyridine and pyridobenzoxazine derivatives
  申请人：Abbott Laboratories

  公开号：US05137892A1

  公开（公告）日：1992-08-11

  Novel antibacterial compounds are disclosed having the formula ##STR1## as well as pharmaceutically acceptable salts, esters, amide and prodrugs thereof, wherein R.sup.1 is selected from the group consisting of (a) lower alkyl, (b) halo(lower alkyl), (c) lower alkyl(alkynyl), (d) lower cycloalkyl, (e) lower alkylamino, (f) nitrogen-containing aromatic heterocycle, (g) bicyclic alkyl and (h) phenyl; R.sup.2 is selected from the group consisting of hydrogen, lower alkyl, a pharmaceutically acceptable cation, and a prodrug ester group; R.sup.3 and R.sup.4 are independently selected from the group consisting of hydrogen, halogen, amino, and lower alkyl; R.sup.5 is either a nitrogen-containing heterocycle or a nitrogen-containing spiro-bicyclic-heterocycle; and A is N or C--R.sup.6, wherein R.sup.6 is selected from the group consisting of hydrogen, halogen, lower alkyl, and lower alkoxy, or R.sup.1 and R.sup.6 taken together with the atoms to which they are attached form a 6-membered ring which may contain an oxygen or sulfur atom and which may be substituted with lower alkyl; as well as pharmaceutical compositions comprising such novel compounds and the thereapeutic use thereof.

  披露了具有公式##STR1##的新型抗菌化合物，以及药学上可接受的盐、酯、酰胺和前药，其中R.sup.1选自以下组：(a)低级烷基，(b)卤代(低级烷基)，(c)低级烷基(炔基)，(d)低级环烷基，(e)低级烷基氨基，(f)含氮的芳香杂环，(g)双环烷基和(h)苯基；R.sup.2选自氢、低级烷基、药学上可接受的阳离子和前药酯基组；R.sup.3和R.sup.4独立选自氢、卤素、氨基和低级烷基；R.sup.5是含氮杂环或含氮螺环双杂环；A是N或C--R.sup.6，其中R.sup.6选自氢、卤素、低级烷基和低级烷氧基，或者R.sup.1和R.sup.6与它们所连接的原子一起形成一个可能含有氧或硫原子的6元环，该6元环可能被低级烷基取代；以及包含这些新型化合物的药物组合物及其治疗用途。
• 1-Substituted-4-(1,2-diphenylethyl)piperazine derivatives and
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：US04080453A1

  公开（公告）日：1978-03-21

  1-Substituted-4-(1,2-diphenylethyl)piperazine derivatives of the formula: ##STR1## wherein X is 2- or 3-hydroxy, 2-methoxy, 3-methyl, 3-alkoxy having 1 to 4 carbon atoms, or 2- or 3-alkanoyloxy having 2 to 5 carbon atoms; R is allyl, 3-hydroxyisoamyl, 3-methyl-2-butenyl, 3-methyl-3-butenyl, propyl, an unsubstituted monocycloalkyl having 5 to 8 carbon atoms, 2-chlorophenyl, or a phenyl substituted by hydroxy or methoxy; with proviso that when X is a substituent at position 2, R is cyclohexyl and when X is 3-methyl, R is 2-methoxyphenyl or an unsubstituted monocycloalkyl having 6 to 8 carbon atoms, and their pharmaceutically acceptable salts, and the preparation thereof, and analgesic or antitussive compositions containing the same as the essentially active ingredient.

  1-取代-4-(1,2-二苯乙基)哌嗪衍生物的化学式为：##STR1## 其中X为2-或3-羟基，2-甲氧基，3-甲基，3-烷氧基（碳原子数为1至4），或2-或3-烷酰氧基（碳原子数为2至5）；R为烯丙基，3-羟基异戊基，3-甲基-2-丁烯基，3-甲基-3-丁烯基，丙基，未取代的含有5至8个碳原子的单环烷基，2-氯苯基，或被羟基或甲氧基取代的苯基；但当X为2位置的取代基时，R为环己基，当X为3-甲基时，R为2-甲氧基苯基或未取代的含有6至8个碳原子的单环烷基，以及其药学上可接受的盐，其制备方法，以及含有其作为基本活性成分的镇痛或止咳组合物。
• Amino acid derivatives and antihypertensive drugs containing them
  申请人：Ajinomoto Co., Inc.

  公开号：US04536395A1

  公开（公告）日：1985-08-20

  N-terminal phosphorus dipeptides having antihypertensive properties are disclosed.

  N-末端磷二肽具有降压作用。